{"id":"gr1802-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, GR1802 injection blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on T-cell activation and proliferation, leading to enhanced anti-tumor immune responses.","oneSentence":"GR1802 injection is a monoclonal antibody targeting the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:13.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT07199257","phase":"PHASE3","title":"A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.","status":"NOT_YET_RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2025-09-25","conditions":"Allergic Rhinitis, Seasonal","enrollment":144},{"nctId":"NCT07154342","phase":"PHASE3","title":"A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis","status":"RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2025-08-15","conditions":"Allergic Rhinitis, Seasonal","enrollment":150},{"nctId":"NCT06315426","phase":"PHASE2","title":"A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2024-03-24","conditions":"Allergic Rhinitis","enrollment":240},{"nctId":"NCT06642961","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma","status":"UNKNOWN","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2022-07-19","conditions":"Asthma","enrollment":150},{"nctId":"NCT05873803","phase":"PHASE2","title":"The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2023-02-08","conditions":"Chronic Rhinosinusitis with Nasal Polyps","enrollment":70},{"nctId":"NCT06216392","phase":"PHASE3","title":"Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis","status":"UNKNOWN","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2024-01","conditions":"Atopic Dermatitis","enrollment":450},{"nctId":"NCT06015243","phase":"PHASE2","title":"The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps","status":"UNKNOWN","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2023-08-18","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GR1802 injection","genericName":"GR1802 injection","companyName":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","companyId":"genrix-shanghai-biopharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GR1802 injection is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}